BlackRock Inc. Raises Stock Position in Abbott Laboratories $ABT

Key Points

• BlackRock increased its Abbott Laboratories stake by 4.6% in the second quarter, acquiring 6.77 million additional shares and bringing its holdings to 152.56 million shares, or approximately 8.82% of the company.
• Abbott reported quarterly earnings of $1.31 per share and revenue of $12.59 billion, exceeding analyst estimates, while revenue grew 13% year over year. Management guided for fiscal 2026 earnings of $5.45–$5.60 per share.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $119.50. Abbott also announced a quarterly dividend of $0.63 per share, representing a 2.2% annualized yield.

BlackRock Inc. increased its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 4.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 152,563,476 shares of the healthcare product maker's stock after acquiring an additional 6,769,518 shares during the period. BlackRock Inc. owned approximately 8.82% of Abbott Laboratories worth $13,843,610,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at $26,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

ABT opened at $112.63 on Friday. The stock's 50 day simple moving average is $102.61 and its 200 day simple moving average is $100.22. The stock has a market cap of $194.89 billion, a P/E ratio of 36.45, a P/E/G ratio of 2.16 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories's revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients age two and older. The wearable is the first of its kind to track both glucose and ketones, strengthening Abbott’s position in diabetes care and creating potential for future integration with insulin-pump systems. FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is designed to reduce stroke risk in certain atrial-fibrillation patients and may reduce reliance on blood-thinning medication, supporting growth in Abbott’s structural-heart business. Abbott's next-generation Amulet 360 device receives CE Mark
• Positive Sentiment: Analyst coverage remains supportive, with TD Cowen expecting Abbott’s stock to rise. Separately, Zacks highlighted ABT as a strong long-term momentum candidate, suggesting improving price trends and investor interest despite its premium valuation. TD Cowen Analyst Says Abbott Stock Price Expected to Rise
• Neutral Sentiment: Abbott’s latest reported quarter exceeded consensus estimates, with earnings and revenue growing year over year. Management’s 2026 earnings guidance also points to continued expansion, but ABT’s elevated price-to-earnings ratio leaves the stock sensitive to execution and valuation concerns.
• Negative Sentiment: Recent coverage noted that Abbott shares fell 2.2% in the prior session even as the broader market advanced, reflecting near-term underperformance and possible profit-taking. The stock remains well below its 12-month high, so investors may want evidence that the new devices translate into meaningful sales growth. Abbott Stock Sinks as Market Gains

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Weiss Ratings raised Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Bank of America lowered their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target for the company. Finally, Citigroup increased their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source